Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Tenosynovial giant cell tumors (TGCT) are locally aggressive tumors that are often difficult to treat surgically due to their size and diffuse growth. Systemic therapies targeting the colony-stimulating factor-1 (CSF-1) pathway have emerged as alternatives. This study assessed the safety and efficacy of lacnotuzumab, a monoclonal antibody against CSF-1.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
